Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(3.53) per share which missed the analyst consensus estimate of $...
Leerink Partners analyst Marc Goodman initiates coverage on LENZ Therapeutics (NASDAQ:LENZ) with a Outperform rating and ann...
William Blair analyst Tim Lugo initiates coverage on LENZ Therapeutics (NASDAQ:LENZ) with a Outperform rating.
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hour...
Citigroup analyst Yigal Nochomovitz initiates coverage on LENZ Therapeutics (NASDAQ:LENZ) with a Buy rating and announces Pr...
LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates si...
LNZ100 selected as lead candidate Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines ...
Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST
